Norris Medicines Limited (BOM:524414)
12.87
-1.42 (-9.94%)
At close: Jan 21, 2026
Norris Medicines Revenue
Norris Medicines had revenue of 20.00M INR in the quarter ending September 30, 2025, with 57.71% growth. This brings the company's revenue in the last twelve months to 72.84M, up 76.48% year-over-year. In the fiscal year ending March 31, 2025, Norris Medicines had annual revenue of 58.20M with 3.27% growth.
Revenue (ttm)
72.84M
Revenue Growth
+76.48%
P/S Ratio
1.87
Revenue / Employee
2.21M
Employees
33
Market Cap
136.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 58.20M | 1.85M | 3.27% |
| Mar 31, 2024 | 56.36M | -27.23M | -32.58% |
| Mar 31, 2023 | 83.59M | -10.80M | -11.44% |
| Mar 31, 2022 | 94.38M | -28.13M | -22.96% |
| Mar 31, 2021 | 122.51M | 44.07M | 56.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunrest Lifescience | 520.34M |
| Cian Healthcare | 232.80M |
| Beryl Drugs | 191.97M |
| Unjha Formulations | 141.50M |
| Zenith Healthcare | 112.08M |
| Hamps Bio | 71.20M |
| Desh Rakshak Aushdhalaya | 62.53M |
| Colinz Laboratories | 58.72M |